Acarix A/S
Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease rule-out. The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to analyze the patient's coronary blood flow. It sells its products in the Nordic countries, the United Kingdom, Germany, Switzerland, Austria, Mauri… Read more
Acarix A/S (ACARIX) - Net Assets
Latest net assets as of December 2025: Skr38.17 Million SEK
Based on the latest financial reports, Acarix A/S (ACARIX) has net assets worth Skr38.17 Million SEK as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr48.33 Million) and total liabilities (Skr10.16 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr38.17 Million |
| % of Total Assets | 78.98% |
| Annual Growth Rate | 8.78% |
| 5-Year Change | -62.04% |
| 10-Year Change | -75.46% |
| Growth Volatility | 343.63 |
Acarix A/S - Net Assets Trend (2014–2025)
This chart illustrates how Acarix A/S's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Acarix A/S (2014–2025)
The table below shows the annual net assets of Acarix A/S from 2014 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr38.17 Million | -49.57% |
| 2024-12-31 | Skr75.70 Million | +45.89% |
| 2023-12-31 | Skr51.88 Million | +0.12% |
| 2022-12-31 | Skr51.83 Million | -48.46% |
| 2021-12-31 | Skr100.54 Million | +22.41% |
| 2020-12-31 | Skr82.14 Million | +7.22% |
| 2019-12-31 | Skr76.60 Million | -12.83% |
| 2018-12-31 | Skr87.88 Million | -31.85% |
| 2017-12-31 | Skr128.94 Million | -17.09% |
| 2016-12-31 | Skr155.52 Million | +1181.13% |
| 2015-12-31 | Skr12.14 Million | -19.73% |
| 2014-12-31 | Skr15.12 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Acarix A/S's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 60046800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr11.65 Million | 30.51% |
| Other Comprehensive Income | Skr2.44 Million | 6.39% |
| Other Components | Skr686.27 Million | 1797.88% |
| Total Equity | Skr38.17 Million | 100.00% |
Acarix A/S Competitors by Market Cap
The table below lists competitors of Acarix A/S ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Helbor Empreendimentos S.A
SA:HBOR3
|
$28.87 Million |
|
MEITAV INVESTMENTS HOUSE R1 RIGHTS
TA:MTAV
|
$28.87 Million |
|
Adveritas Ltd
AU:AV1
|
$28.87 Million |
|
Chungdamglobal Co. Ltd.
KQ:362320
|
$28.87 Million |
|
Téléverbier SA
PA:TVRB
|
$28.85 Million |
|
Borosil Scientific
NSE:BOROSCI
|
$28.85 Million |
|
Nordic Aqua Partners As
OL:NOAP
|
$28.84 Million |
|
ICD Tan Cang Long Binh JSC
VN:ILB
|
$28.84 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Acarix A/S's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 75,697,000 to 38,171,000, a change of -37,526,000 (-49.6%).
- Net loss of 48,091,000 reduced equity.
- Share repurchases of 11,105,000 reduced equity.
- New share issuances of 11,105,000 increased equity.
- Other comprehensive income decreased equity by 2,774,000.
- Other factors increased equity by 13,339,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-48.09 Million | -125.99% |
| Share Repurchases | Skr11.11 Million | -29.09% |
| Share Issuances | Skr11.11 Million | +29.09% |
| Other Comprehensive Income | Skr-2.77 Million | -7.27% |
| Other Changes | Skr13.34 Million | +34.95% |
| Total Change | Skr- | -49.57% |
Book Value vs Market Value Analysis
This analysis compares Acarix A/S's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.86x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.40x to 8.86x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | Skr0.75 | Skr0.30 | x |
| 2015-12-31 | Skr0.56 | Skr0.30 | x |
| 2016-12-31 | Skr5.96 | Skr0.30 | x |
| 2017-12-31 | Skr2.81 | Skr0.30 | x |
| 2018-12-31 | Skr1.73 | Skr0.30 | x |
| 2019-12-31 | Skr2.02 | Skr0.30 | x |
| 2020-12-31 | Skr0.77 | Skr0.30 | x |
| 2021-12-31 | Skr0.60 | Skr0.30 | x |
| 2022-12-31 | Skr0.20 | Skr0.30 | x |
| 2023-12-31 | Skr0.11 | Skr0.30 | x |
| 2024-12-31 | Skr0.08 | Skr0.30 | x |
| 2025-12-31 | Skr0.03 | Skr0.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Acarix A/S utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -125.99%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -653.32%
- • Asset Turnover: 0.15x
- • Equity Multiplier: 1.27x
- Recent ROE (-125.99%) is below the historical average (-83.84%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -127.02% | 0.00% | 0.00x | 1.21x | Skr-20.72 Million |
| 2015 | -102.09% | 0.00% | 0.00x | 1.28x | Skr-13.61 Million |
| 2016 | -31.02% | 0.00% | 0.00x | 1.11x | Skr-63.79 Million |
| 2017 | -23.09% | -4667.08% | 0.00x | 1.04x | Skr-42.67 Million |
| 2018 | -48.10% | -4128.03% | 0.01x | 1.08x | Skr-51.06 Million |
| 2019 | -60.65% | -2501.83% | 0.02x | 1.08x | Skr-54.12 Million |
| 2020 | -50.58% | -1914.65% | 0.02x | 1.10x | Skr-49.76 Million |
| 2021 | -51.52% | -1377.71% | 0.03x | 1.18x | Skr-61.86 Million |
| 2022 | -148.55% | -1322.31% | 0.08x | 1.34x | Skr-82.17 Million |
| 2023 | -150.02% | -1247.22% | 0.10x | 1.21x | Skr-83.03 Million |
| 2024 | -87.44% | -1067.19% | 0.08x | 1.07x | Skr-73.76 Million |
| 2025 | -125.99% | -653.32% | 0.15x | 1.27x | Skr-51.91 Million |
Industry Comparison
This section compares Acarix A/S's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $92,512,974
- Average return on equity (ROE) among peers: -94.39%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Acarix A/S (ACARIX) | Skr38.17 Million | -127.02% | 0.27x | $28.86 Million |
| Arcoma AB (ARCOMA) | $39.03 Million | -4.06% | 0.95x | $8.51 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $144.60 Million | -26.53% | 3.87x | $19.62 Million |
| CellaVision AB (CEVI) | $124.91 Million | 5.16% | 0.43x | $263.99 Million |
| Clinical Laserthermia Systems AB (publ) (CLS-B) | $17.06 Million | -157.93% | 0.60x | $13.31 Million |
| Chordate Medical Holding AB (CMH) | $25.64 Million | -77.06% | 0.22x | $17.64K |
| Coala Life Group AB (COALA) | $39.33 Million | -360.87% | 1.68x | $468.93K |
| C-Rad AB (publ) (CRAD-B) | $347.20 Million | 3.02% | 0.44x | $55.46 Million |
| Duearity AB (DEAR) | $11.04 Million | -140.58% | 0.46x | $34.43K |
| Episurf Medical AB (publ) (EPIS-B) | $83.80 Million | -90.69% | 0.17x | $5.40 Million |